PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frontier BioSciences, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frontier BioSciences, Inc. Signs Agreement with Top China-based Preclinical CRO - Formalized partnership enhances pre-clinical drug development services - FrontierBSI.com
Frontier BioSciences, Inc. Signs Agreement with Top China-based Preclinical CRO

 

NewswireToday - /newswire/ - Germantown, MD, United States, 2007/03/02 - Formalized partnership enhances pre-clinical drug development services - FrontierBSI.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frontier BioSciences, Inc. today announced that it has signed a formal agreement with the National Chengdu Center for Safety Evaluation of Drugs (NCCSED) to become shareholder and strategic partner in the preclinical contract research service business.

NCCSED was established in 2000 by West China Hospital (WCH) of Sichuan University. Since its inception, this full service preclinical contract research laboratory has become one of the top drug safety evaluation centers in China having received GLP certification by China’s State Food and Drug Administration (SFDA) in 2004. In addition, the NCCSED has been awarded multiple grants from the Ministry of Sciences and Technologies of China. Covering an area of 80,000 sq. ft., this state-of-the-art toxicology facility is comprised of a small SPF animal facility and a conventional large animal facility, equipped with the latest advanced technology and operated by experienced staff with international CRO experience. It has conducted safety and efficacy studies for more than 60 preclinical candidates in the past three years.

“With the NCCSED’s extensive preclinical toxicology experience and unblemished reputation, along with Frontier’s U.S.-trained technical and quality assurance staff, we are poised to provide high-quality and cost-effective services to our customers. We are committed to being a global partner and assisting our customers to move product candidates toward clinic and marketplace”, noted Frontier’s President, Dong Xie, Ph.D.

Additionally, NCCSED’s Director, Li Wang, Ph.D., commented by saying, “With the full technical support of WCH, the largest hospital in Asia with comprehensive teaching and research facility for all medical disciplines, the new partnership will bring online a wide range of preclinical and clinical drug development services, while delivering speed, quality, and economy at international standard. This partnership expands our current capabilities, and displays our commitment to providing top-tier scientific services to customers.”

About Frontier BioSciences, Inc.

Frontier BioSciences, Inc. (frontierbsi.com) is a Maryland-based company providing drug development services for biotechnology and pharmaceutical companies. The company was founded by a team of industry experts, with a strong scientific base in China, as well as extensive CRO experience from the U.S. and Canada. The company has strength in program management, marketing and business development, and international regulatory guidance.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frontier BioSciences, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frontier BioSciences, Inc. Signs Agreement with Top China-based Preclinical CRO

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Beth Wong - FrontierBSI.com 
301-251-0231 bwong[.]frontierbsi.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frontier BioSciences, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frontier BioSciences, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)